Satellos Bioscience Inc.

NASDAQ: MSLE · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Toronto, ONReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 50DQ —GM —SS 48

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$24.9M

Employees

Market cap

$9.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$24.9M-$24.9M2025

Operating income-$26.5M-$26.5M2025

Total assets$31.9M$31.9M2025

Liabilities$4.1M$4.1M2025

Equity$27.8M$27.8M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Satellos Bioscience Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Plus Therapeutics, Inc.38D Adagio Medical Holdings, Inc.24D Modular Medical, Inc.34D PharmaCielo Ltd.40D

Key facts

CEOFrank Gleeson

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersToronto, ON

ExchangeNASDAQ: MSLE

Employees18

IPO date2012-08-03

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.